{"entity":{"id":"idea-reg-open-source-lentiviral-vectors","kind":"idea","name":"Non-profit, open-licence lentiviral vectors and producer cell lines for CAR-T","aka":[],"tldr":"The engineered virus that delivers the CAR gene costs tens of thousands of dollars per patient and is controlled by a few suppliers. A non-profit supplier with open licences would cut that cost sharply.","summary":"Vector is often the single largest material cost in autologous CAR-T and a frequent cause of manufacturing delay; capacity is concentrated among a few contract suppliers and licences are restrictive. Caring Cross and several academic centres have shown that non-profit vector production can supply clinical programmes at a fraction of the cost. The proposal is a foundation-funded vector consortium with stable producer cell lines, a shared plasmid bank for common CARs (CD19, BCMA, CD22) under open licences for non-commercial and low-income-country use, and GMP production at cost.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Manufacturing cost and time for living and radioactive medicines): Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018)","url":"https://doi.org/10.1001/jamaoncol.2018.0977"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["car-t"],"targets":["cd19","bcma"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-manufacturing-cell-therapy","b-global-access"],"keyPapers":["paper-hernandez-jama-oncol"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Consortium vector supplied at cost reduces vector cost per CAR-T dose to below $5,000 and enables at least ten new academic or LMIC CAR-T programmes to reach the clinic within five years.","rationale":"Vector production is a mature process whose price reflects concentration and licensing more than inherent cost; stable producer lines remove the plasmid transfection step that drives variability and expense.","test":"Fund the consortium to produce GMP vector for three academic CD19 programmes, audit cost per dose and release success rate against commercial contract supply, and count new programmes enabled.","maturity":"early-clinical","actor":"philanthropy","cost":"medium","horizonYears":3},"route":"/ideas/idea-reg-open-source-lentiviral-vectors/","neighbours":{"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"target":[{"id":"bcma","kind":"target","name":"BCMA","route":"/targets/bcma/"},{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"}],"bottleneck":[{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/"},{"id":"b-global-access","kind":"bottleneck","name":"Most of the world has almost no cancer care","route":"/bottlenecks/b-global-access/"}],"paper":[{"id":"paper-hernandez-jama-oncol","kind":"paper","name":"Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy","route":"/key-papers/paper-hernandez-jama-oncol/"}]}}